What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19

Miller, Andrew C.; D'Silva, Yannick A

doi:10.4103/ijciis.ijciis_80_21

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other methods that JAKi use to paradoxically improve the anti-viral response are as follows: (1) reduction of interferon-mediated ACE2 up‐regulation or (2) control of lymphopenia arising from overdominance of myelopoiesis in excessive acute-phase response, and (3) decreasing activated T-lymphocytes and natural killer cells to diminish cytotoxic tissue damage. [ 28 29 ]…”

Section: Mechanism Of Actionmentioning

confidence: 99%

A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019

Hashemian,

Farhadi

2023

International Journal of Critical Illness and Injury Science

View full text Add to dashboard Cite

In coronavirus disease 2019 (COVID-19), the formation of cytokine storm may have a role in worsening of the disease. By attaching the cytokines like interleukin-6 to the cytokine receptors on a cell surface, Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway will be activated in the cytoplasm lead to hyperinflammatory conditions and acute respiratory distress syndrome. Inhibition of JAK/STAT pathway may be useful to prevent the formation of cytokine storm. Tofacitinib is a pan inhibitor of JAKs. In this review, the main characteristics of tofacitinib and its usefulness against COVID-19 pneumonia were reviewed. Tofacitinib may be a hopeful therapeutic candidate against COVID-19 respiratory injury since it inhibits a range of inflammatory pathways. Hence, the agent may be considered a potential therapeutic against the post-COVID-19 respiratory damage. Compared to other JAK inhibitors (JAKi), the administration of tofacitinib in COVID-19 patients may be safer and more effective. Other JAKi such as baricitinib are related to severe adverse events such as thrombotic events compared to more common side effects of tofacitinib.

show abstract

Section: Mechanism Of Actionmentioning

confidence: 99%